Core Viewpoint - Jupiter Neurosciences, Inc. has announced the addition of Chris Webber as the second brand ambassador for its new longevity supplement line, Nugevia™, which is based on clinical science and innovative performance-driven technology [1][3]. Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy that includes advancing therapeutics for CNS disorders and entering the consumer longevity market with Nugevia™ [7]. - The company’s proprietary JOTROL™ platform enhances the bioavailability of resveratrol, which is the foundation for both its therapeutic pipeline and the Nugevia™ product line [10]. Product Details - Nugevia™ features three initial formulations—GLO, MND, and PWR—designed to support cellular resilience through synergistic ingredients optimized for absorption via the JOTROL™ system [4]. - The Nugevia™ brand aims to tap into the rapidly growing longevity market, projected to reach $8 trillion by 2030, creating a revenue stream to support ongoing clinical development and enhance long-term shareholder value [5][6]. Scientific Validation - JOTROL™ has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, as evidenced by a Phase I study published in reputable journals [9]. - The technology aims to provide pharmaceutical-grade bioavailability in the wellness space, targeting cognitive health, skin vitality, and cellular energy [10].

Core Insights - Jupiter Neurosciences, Inc. is advancing its proprietary resveratrol-based platform, JOTROL, which offers significant advantages over traditional resveratrol formulations [1][3][10] - JOTROL has demonstrated a nine-fold increase in bioavailability compared to conventional resveratrol, while avoiding gastrointestinal side effects [3][7][10] - The company is progressing JOTROL towards a Phase IIa trial for Parkinson's Disease, supported by promising preclinical data [4][8][10] Scientific and Clinical Advantages - Resveratrol is known for its antioxidant, mitochondrial, and anti-inflammatory properties, but its therapeutic use has been limited due to poor bioavailability and GI side effects [2][9] - JOTROL promotes mitochondrial biogenesis and reduces neuroinflammation, addressing key factors in neurodegenerative diseases and aging [5][6] Product Development and Market Strategy - JOTROL is not only aimed at pharmaceutical applications but also serves as the foundation for the Nugevia consumer product line, targeting cognitive health, mitochondrial energy, and skin vitality [4][11] - The Nugevia product line is set to launch in Q3 2025, leveraging the same delivery technology as JOTROL to provide clinical-grade bioavailability in the wellness market [11] Intellectual Property and Market Potential - The company has secured intellectual property rights for JOTROL in major markets including the U.S., EU, China, Japan, and Hong Kong, valid through 2036 [7] - JOTROL's ability to cross the blood-brain barrier positions it as a potential treatment for CNS disorders such as Parkinson's and Alzheimer's [7][8]

As filed with the U.S. Securities and Exchange Commission on January 6, 2023 Registration No. 333-260183 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 16 TO Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-4828381 (Primary Standard Industrial Classification Code Number) (I.R.S. ...